Launches

Eyeing the lucrative opportunity, three Indian players have launched their generic versions of Boehringer’s anti-diabetes drug Jardiance in their domestic market.

Celltrion has become the latest firm to enter the competitive US market for Stelara biosimilars, revealing details of its Steqeyma launch.

Lupin has moved quickly to begin rolling out the first generic version of the blockbuster blood thinner Xarelto in the US, despite continued legal action over a patent expiring in 2039.

In the wake of multiple ustekinumab biosimilar rivals to Stelara launching in the US at the end of February, Generics Bulletin’s editors discuss the market dynamics and the latest key developments.

Amgen has confirmed to Generics Bulletin details of its launch of Bkemv, the first US biosimilar to Soliris.

Fresenius has become the latest firm to launch a Stelara biosimilar in both the US and Europe, bringing partner Formycon’s Otulfi version to market. But with heavy discounting already seen in the US and multiple competitors already established in the EU, will the firm be able to stand out from the crowd?

Viatris is beginning to deliver on at least one of its complex generic injectables – long-promised by the US company as part of a deep and differentiated pipeline – as it pledged to provide further details at the firm’s upcoming company investor day.

Biocon has announced the UK launch of its liraglutide generic rivals to Victoza and Saxenda, hailing a “significant milestone” for the firm’s GLP-1 business, which it expects to be a major growth driver in years to come.

Scrip spoke with Bayer commercial and business development heads Christine Roth and Jurgen Eckhardt about sales growth, product launches and dealmaking priorities in 2025 and beyond.

Abbott is now offering its consumer CGM Lingo at Amazon for $49 for a single sensor. Its rival Dexcom also expects to introduce its consumer CGM Stelo on Amazon in Q1.